

Table S1. Patient disposition

Disposition/Reason	All Patients N=33 n (%)
DDI phase (pharmacokinetic evaluation)	
Completed	18 (54.5)
Discontinued from DDI phase	15 (45.5)
Permanently discontinued the study	12 (36.4)
Primary reason for discontinuation from DDI phase	
Adverse event	8 (24.2)
Progressive disease	6 (18.2)
Death	1 (3.0)
Treatment phase (DDI phase + post-DDI phase)	
Discontinued from treatment phase	33 (100)
Primary reason for discontinuation from treatment phase	
Adverse event	6 (18.2)
Study terminated by sponsor	12 (36.4)
Progressive disease	13 (39.4)
Subject/guardian decision	1 (3.0)
Death	1 (3.0)